Although the general significance of these in vitro data in the context of cancer treatment is limited, they strongly support the importance of an anticancer therapy based on a combined treatment of Sorafenib with inhibitors of the Trx system or other prooxidant agents for advanced HCC and encourage the undertaking of further research on this ground. This evidence concerns the gene TXN and hepatocellular carcinoma.